Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy

$267m Deal Expands Biotech’s Research

Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.

Brain scan
After starting with liver diseases, MiNA will now look to target neurodegenerative diseases

Servier has signed a deal with MiNA Therapeutics to develop novel small activating RNA (saRNA) therapies in neurological disorders.

The London-based biotech’s technology is based on the work of pioneering liver disease drug developer and surgeon Nagy Habib, who...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip